{
  "research_id": "CA_eval_20260220-1411_LLY",
  "type": "ca_eval",
  "ticker": "LLY",
  "created_at": "2026-02-20T14:11:00Z",
  "completed_at": "2026-02-20T16:15:00Z",
  "parameters": {
    "ticker": "LLY",
    "report_path": "analyst/raw/LLY US.md",
    "skip_industry": true
  },
  "model_config": {
    "lead": "claude-sonnet-4-6 (inherit)",
    "teammates": "sonnet"
  },
  "status": "completed",
  "workflow": {
    "phase_0": "done",
    "phase_1": "done",
    "phase_2": "done",
    "phase_3": "done",
    "phase_4": "done"
  },
  "task_results": {
    "T0_setup": { "status": "completed", "owner": "ca-eval-lead", "output": "00_meta/research-meta.json" },
    "T1_sec_filings": { "status": "completed", "owner": "ca-eval-lead", "output": "01_data_collection/sec-data.json" },
    "T2_report_parser": { "status": "completed", "owner": "ca-eval-lead", "output": "01_data_collection/parsed-report.json" },
    "T3_industry": { "status": "skipped", "owner": "ca-eval-lead", "note": "PoC段階のポリシーによりスキップ（SEC EDGAR以外の外部データソース不使用）" },
    "T4_claim_extractor": { "status": "completed", "owner": "ca-eval-lead", "output": "02_claims/claims.json" },
    "T5_fact_checker": { "status": "completed", "owner": "ca-eval-lead", "output": "03_verification/fact-check.json" },
    "T6_pattern_verifier": { "status": "completed", "owner": "ca-eval-lead", "output": "03_verification/pattern-verification.json" },
    "T7_report_generator": { "status": "completed", "owner": "ca-eval-lead", "output": ["04_output/draft-report.md", "04_output/structured.json"] },
    "T8_ai_critique": {
      "status": "completed",
      "owner": "ca-eval-lead",
      "output": ["04_output/critique.json", "04_output/revised-report.md"],
      "verdict": {
        "critical_issues": 1,
        "minor_issues": 5,
        "confidence_changes": 0,
        "annotation_additions": 6
      }
    },
    "T9_accuracy": {
      "status": "completed",
      "owner": "ca-eval-lead",
      "output": "04_output/accuracy-report.json",
      "verdict": "pass",
      "mode": "full",
      "ca_average_deviation_pct": 0.0,
      "cagr_average_deviation_pct": 0.0
    }
  },
  "outputs": {
    "final_report": "04_output/revised-report.md",
    "draft_report": "04_output/draft-report.md",
    "structured_json": "04_output/structured.json",
    "critique": "04_output/critique.json",
    "accuracy": "04_output/accuracy-report.json"
  },
  "summary": {
    "avg_ca_confidence": 47,
    "avg_cagr_confidence": 56,
    "total_claims": 7,
    "distribution": { "90pct": 0, "70pct": 1, "50pct": 3, "30pct": 3, "10pct": 0 },
    "strongest_claims": ["LLY-CA-1（経口低分子GLP-1技術力: CA=70%、CAGR=70%）"],
    "kb3_closest_analog": "fewshot_LLY.md（平均47%）と完全一致",
    "notable_t8_modification": "LLY-CA-2のCAGR評価コメントに「製品ミックス変化がマージン改善を相殺する可能性」（KB3 #1明示リスク）を追記。根源要因（中外製薬ライセンス取得経緯）の説明不足をCA-1の90%未満の主要根拠として明示化。",
    "accuracy_check": {
      "mode": "full",
      "verdict": "pass",
      "ca_average_deviation_pct": 0.0,
      "cagr_average_deviation_pct": 0.0,
      "matched_claims": 6,
      "unmatched_claims": 1
    }
  }
}
